| Description | Cyclovirobuxine D (Bebuxine) is extracted from Buxus microphylla. |
| In vitro | 小鼠体内Cyclovirobuxine D的LD50: 8.9 mg/kg（i.v.）、9.2 mg/kg（i.p.）、293 mg/kg（p.o.）.Cyclovirobuxine D可使大鼠体内静脉血栓的重量减少.在麻醉的猪体内,其可引起冠状动脉血管舒张的初始作用,这与内皮细胞中一氧化氮释放的机制有关.此外,Cyclovirobuxine D还对大鼠体内心肌梗死诱发的心脏衰竭有改善作用. |
| In vivo | Cyclovirobuxine D对细胞内的Ca(2+)利用有促进作用,并防止Ca(2+)流失,从而实现其对心脏衰竭的保护作用。Cyclovirobuxine D可使氧化或缺氧损伤的心肌细胞活性增加。Cyclovirobuxine D可使大鼠体内结扎冠状动脉造成的梗死面积显著减少。Cyclovirobuxine D还可使大鼠主动脉内皮细胞免受缺氧造成的损伤,并增强内皮细胞中NO的释放。 |
| Synonyms | 黄杨碱, CVB-D, Bebuxine, Cyclovirobuxin D, 环维黄杨星D |
| molecular weight | 402.66 |
| Molecular formula | C26H46N2O |
| CAS | 860-79-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: 13 mg/mL (32.29 mM; Need ultrasonic) H2O: Insoluble DMSO: Insoluble, Sonication is recommended. |
| References | 1. Hu D, et al. Eur J Pharmacol, 2007, 569(1-2), 103-109. 2. Grossini E, et al. Life Sci, 1999, 65(5), PL59-65. 3. Yu B, et al. Fitoterapia. 2011, 82(6), 868-877. 4. Yu B, et al. Fitoterapia. 2012, 83(8):1653-1665. |
| Kinase | MDA-MB-231 cells treated as indicated or tumor tissues are harvested and lysed in Mg2+ lysis buffer containing 50 mM Tris (pH 7.5), 10 mM MgCl2, 0.5 M NaCl, and protease inhibitor cocktail. Equal amounts of lysates are incubated with PAK-PBD beads at 4°C for 1 h. PAK-PBD beads are pelleted by centrifugation and washed with ish buffer containing 25 mM Tris (pH 7.5), 30 mM MgCl2, 40 mM NaCl. Active Rac1 is detected by western blotting. |